We revealed that RLY01, with low toxicity, markedly impeded the growth of KRAS-mutant lung cancer organoids in vitro and tumor development in several preclinical mouse models in vivo, including colorectal cancer lung cancer xenografts. This evidence concerns the gene KRAS and colorectal cancer.